The Alzheimer's Disease Research Center (ADRC) at Johns Hopkins University (JHU) consists of 5 Cores: (1) the Administrative Core;(2) the Clinical Core;(3) the Data Management and Statistics Core;(4) the Neuropathology Core;and (5) the Education Core. These Cores interact with each other, in order to stimulate and support Alzheimer's disease (AD) research throughout JHU. In the current funding cycle, ADRC investigators have published 324 peer-reviewed articles and 24 chapters on aging and age-related degenerative disorders. Of these, 108 peer-reviewed publications are directly related to projects supported by the involvement of ADRC subjects. The ADRC has been associated with 21 projects that have been supported by the enrollment of ADRC subjects and 31 projects that have been supported by the provision of brain tissue or other specimens. In the next funding cycle, Center funds will directly support three research Projects: Project 1 (PI - Dr. R. O'Brien) - """"""""The roles of amyloid, tau, and synaptic loss in early AD"""""""";Project 2 (PI - Dr. A. Savonenko) - """"""""Modeling an anti-amyloid therapy for AD: potential for cognitive recovery"""""""" and Project 3 (PI - Dr. P. Wortey) - """"""""Neuronal activity-dependent secretion of A? and immediate early genes"""""""". Each of the Projects is consistent with the guidelines of the RFA: Project 1 takes advantage of brain tissue collected over many years from well characterized subjects in the ADRC (through the collaboration of the Clinical Core and the Neuropathology Core);Project 2. led by a junior investigator, focuses on manipulations of levels of A? species and its influence on behavior and brain biology;and Project 3. led by a senior investigator who is new to the AD field, but whose research on the influences of specific gene products, especially the roles of immediate early genes on synaptic functions, is highly relevant to AD. Together with the large number of associated projects supported by the ADRC, the Center focuses on two Interrelated themes: (1) characterization and understanding of the early clinical and pathological stages of AD in humans;and (2) the identification of the cellular and molecular events that contribute to the clinical abnormalities in animal models. Thus, as in the previous funding cycle, the focus of this application will be on the earliest stages of pathology in humans and in model systems, with the goal of influencing the development of experimental therapeutics that, when introduced Into the clinic, can delay or prevent AD.

Public Health Relevance

The Johns Hopkins Alzheimer's Disease Research Center (ADRC) will address many of the topics important to dementia research, with a particular focus on the understanding the earliest phases of Alzheimer's disease (AD). This approach is important if we are ultimately going to be able to diagnose and treat AD as early as possible. The ADRC fosters interactions among scientists who are pursuing this overarching theme.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
3P50AG005146-30S1
Application #
8607326
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J2))
Program Officer
Phelps, Creighton H
Project Start
1997-07-15
Project End
2015-03-31
Budget Start
2013-08-01
Budget End
2014-03-31
Support Year
30
Fiscal Year
2013
Total Cost
$100,000
Indirect Cost
$38,271
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Kaji, Seiji; Maki, Takakuni; Kinoshita, Hisanori et al. (2018) Pathological Endogenous ?-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy. Stem Cell Reports 10:356-365
Na, Chan Hyun; Barbhuiya, Mustafa A; Kim, Min-Sik et al. (2018) Discovery of noncanonical translation initiation sites through mass spectrometric analysis of protein N termini. Genome Res 28:25-36
Eftekharzadeh, Bahareh; Daigle, J Gavin; Kapinos, Larisa E et al. (2018) Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron 99:925-940.e7
Albert, Marilyn; Zhu, Yuxin; Moghekar, Abhay et al. (2018) Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years. Brain :
Oh, Esther S; Blennow, Kaj; Bigelow, George E et al. (2018) Abnormal CSF amyloid-?42 and tau levels in hip fracture patients without dementia. PLoS One 13:e0204695
Johnson, Erik C B; Dammer, Eric B; Duong, Duc M et al. (2018) Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Mol Neurodegener 13:52
Ganguli, Mary; Albanese, Emiliano; Seshadri, Sudha et al. (2018) Population Neuroscience: Dementia Epidemiology Serving Precision Medicine and Population Health. Alzheimer Dis Assoc Disord 32:1-9
Tsapkini, Kyrana; Webster, Kimberly T; Ficek, Bronte N et al. (2018) Electrical brain stimulation in different variants of primary progressive aphasia: A randomized clinical trial. Alzheimers Dement (N Y) 4:461-472
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10

Showing the most recent 10 out of 830 publications